No Data
Altimmune to Participate at Leerink Partners Therapeutics Forum
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be hosting one-on-one
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Shares of Altimmune Are Trading Higher After a NYPost Article Highlighted a Study Comparing the Company's Pemvidutide to Ozempic.
Shares of Altimmune Are Trading Higher After a NYPost Article Highlighted a Study Comparing the Company's Pemvidutide to Ozempic.
Watching Altimmune; Traders Circulate New Yor Post Article 'New Weight Loss Drug May Be Better Than Ozempic — Here's How'
Watching Altimmune; Traders Circulate New Yor Post Article 'New Weight Loss Drug May Be Better Than Ozempic — Here's How'
Why Are Altimmune Shares Trading Lower Wednesday?
Altimmune, Inc. (NASDAQ:ALT) shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, the company's chief financial officer. What To Know: Eisenstadt'